Verdicts genuinely change. Free email alert the moment ERNAW's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Business activity could not be assessed — classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later
ℹ️ Ratios above can still show Pass — business-activity screening itself couldn't run, and it's a hard gate a ratio pass can't substitute for.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Ernexa Therapeutics Inc. (ERNAW) has not yet been screened, per Halal Terminal (dropped). See the full ratio breakdown and business-activity screen below for the reasoning.
Research only, not the primary verdict above — computed from SEC EDGAR filings and business-activity classification, same as the Discord bot's !halal command.
Business activity: could not be assessed
classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later
The live recompute of the financial screen did not complete for this symbol, so no combined verdict is shown here. That is a statement about our fetch, not about the company — the stored result above stands.
ℹ️ Every methodology's ratios above may show Pass, but the combined verdict still reads Needs Review because business-activity screening itself couldn't run (classifier temporarily unavailable (rate limit or outage) — not a real assessment, try again later) — it's a hard gate, so a real ratio pass can't substitute for it. Re-check this page later once that's resolved.
Computed from the company's own filing, measured against market cap — the AAOIFI basis. Other standards move both the line and the denominator, which is what the breakdown above shows.
Read from ERNAW's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | not measured | — | — |
| Interest-bearing debtBorrowings — which definition was stored is not recorded | not measured | — | — |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | not measured | — | — |
| Total assetsBalance sheet total | not measured | — | — |
| Market capDenominator for AAOIFI | not measured | — | — |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | not measured | — | — |
| 24-month average market capDenominator for Dow Jones Islamic Market | not measured | — | — |
| Non-permissible revenueInterest and excluded income | not measured | — | — |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Verdict history for ERNAW. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
ℹ️ no compliance scan has run for 3 days - this is not a reading of today
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
This fund prices once a day, so its bars carry no intraday high or low — floor-trader pivots are not defined for it.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 37 |
| ⏱ 15-Min | BEARISH | 35 |
| ⏲ 5-Min | BEARISH | 107 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-09-22 · Asset managers net 934455 (+29771)
From the nightly market snapshot, shown so the verdict sits beside the numbers it does not depend on.
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.